In June 2023, Nacuity announced they completed enrollment in the SLO-RP Phase I/II clinical trial of NPI-001 tablets. NPI-001 is a gene agnostic, small molecule oral drug designed to slow progression of retinitis pigmentosa (RP) in patients with functioning cones. They will evaluate the drug tolerability, clinical safety and efficacy of NPI-001 against a placebo in patients with Usher syndrome. Efficacy will be determined by following the participants for up to two years during the study.
What this means for Usher syndrome: As this clinical trial advances, data will be released determining the efficacy of this potential treatment, which will hopefully move through the pipeline.
